Phaseline

Companies › OncoTherapy Science

OncoTherapy Science: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OTS167PO
MELK kinase inhibitor
MELKPhase 1Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast CancerSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02926690OTS167POPhase 1Relapsed/Refractory Locally Advanced or Metastatic Breast Cancer and Triple Negative Breast CancerOncologySep 2027

Targets

MELK (1)

Companies with the same targets

Delcath Systems

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.